Acta Biochim Biophys Sin (Shanghai)

1. JIE Y, Yang Y, Guo C, Wu Q, et al
   The TCF7L2/miR-206/Cofilin1 axis promotes the metastasis of bladder cancer cells by regulating the formation of invadopodia.
   Acta Biochim Biophys Sin (Shanghai). 2025 Aug 6. doi: 10.3724/abbs.2025114.
   

   >> Share

   
   

   
   Adv Sci (Weinh)

2. 
   Correction to "Targeting the KAT8/YEATS4 Axis Represses Tumor Growth and Increases Cisplatin Sensitivity in Bladder Cancer".
   Adv Sci (Weinh). 2025 Aug 4:e13864. doi: 10.1002/advs.202513864.
   

   >> Share

   
   

   
   Afr Health Sci

3. ABDERRAHMANE RK, Touala-Chaila Z, Benseddik K, Hassani N, et al
   Are TP53 Arg72Pro and MDM2 T309G polymorphisms associated with bladder cancer risk? A meta-analysis.
   Afr Health Sci. 2024;24:118-127.
   

   >> Share

   
   

   
   Ann Surg Oncol

4. LIN L, Liu Z, Tang Y, Lin T, et al
   Exploring the Impact of 5-Alpha Reductase Inhibitors on Bladder Cancer: Insights from a Large-Scale Prospective Cohort Study.
   Ann Surg Oncol. 2025 Aug 3. doi: 10.1245/s10434-025-17981.
   

   >> Share

   
   

   
   Anticancer Res

5. OKADA K, Naito Y, Irie S, Nakamoto C, et al
   Novel UF-5000-based Detection, Integrating Inflammatory Parameters, for Urothelial Carcinoma of the Urinary Bladder.
   Anticancer Res. 2025;45:3531-3541.
   

   >> Share

   
   
6. ZHENG M, Lu J, Yu W, Li Y, et al
   Nucleoporin 188 as a Predictive Biomarker of Poor Prognosis in Muscle-invasive Bladder Cancer.
   Anticancer Res. 2025;45:3245-3261.
   

   >> Share

   
   

   
   Arch Esp Urol

7. FENG X, Huang J
   Temozolomide Resistance in Smoking-Related Bladder Cancer through TNFAIP6-Mediated Post-Translational Modifications.
   Arch Esp Urol. 2025;78:732-742.
   

   >> Share

   
   
8. KAYAR R, Kayar K, Tokuc E, Topaktas R, et al
   Value of Preoperative Inflammatory Burden Index in Predicting Overall Survival and Progression in Nonmetastatic Muscle-Invasive Bladder Cancer.
   Arch Esp Urol. 2025;78:660-670.
   

   >> Share

   
   

   
   Beijing Da Xue Xue Bao Yi Xue Ban

9. MIAO Q, Hong B, Zhang X, Sun Z, et al
   [Risk assessment of perioperative adverse events and management of antiplatelet therapy in patients with bladder cancer and coronary atherosclerotic heart disease undergoing transurethral resection of bladder cancer].
   Beijing Da Xue Xue Bao Yi Xue Ban. 2025;57:698-703.
   

   >> Share

   
   

   
   BJU Int

10. DEY L, Rautiola J, Akre O, Egevad L, et al
    Long-term oncological outcomes of bladder cancer: a population-based study with a 25-year follow-up.
    BJU Int. 2025 Aug 7. doi: 10.1111/bju.16883.
    

    >> Share

    
    

    
    Cancer Biol Ther

11. FAN L, Zhou Y, Liu S, Zhuo X, et al
    NR4A3 regulates anoikis resistance and metastasis of bladder cancer through EWSR1.
    Cancer Biol Ther. 2025;26:2535774.
    

    >> Share

    
    
12. CHUN H, Baima K
    Unraveling the dual role of METTL3-mediated m(6)A RNA modification in bladder cancer: mechanisms, therapeutic vulnerabilities, and clinical implications.
    Cancer Biol Ther. 2025;26:2545057.
    

    >> Share

    
    

    
    Cancer Cell Int

13. SHAN L, Liu W, Zhan Y
    Retraction Note: LncRNA HAND2-AS1 exerts anti-oncogenic effects on bladder cancer via restoration of RARB as a sponge of microRNA-146.
    Cancer Cell Int. 2025;25:298.
    

    >> Share

    
    

    
    Cancer Med

14. HATAKEYAMA S, Yamamoto H, Kitamura H, Kamoto T, et al
    Safety of Robot-Assisted Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Real-World Analysis Using the National Clinical Database in Japan.
    Cancer Med. 2025;14:e71109.
    

    >> Share

    
    

    
    Cancer Rep (Hoboken)

15. ARIMA J, Yoshino H, Tatarano S, Mitsuke A, et al
    Prognostic Impact of Clostridium butyricum MIYAIRI (CBM588) in Combination With Pembrolizumab for Advanced Urothelial Carcinoma: A Retrospective Cohort Study.
    Cancer Rep (Hoboken). 2025;8:e70308.
    

    >> Share

    
    

    
    Cancer Res

16. CHEN C, Gao Y, Lu R, Wu Y, et al
    TERC Stimulates Fatty Acid Metabolism to Promote Bladder Cancer Progression.
    Cancer Res. 2025 Aug 4. doi: 10.1158/0008-5472.CAN-24-3439.
    

    >> Share

    
    

    
    Cell Rep Med

17. HOLT MV, Dou Y, Young MN, Saltzman AB, et al
    Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer.
    Cell Rep Med. 2025 Jul 29:102255. doi: 10.1016/j.xcrm.2025.102255.
    

    >> Share

    
    

    
    Clin Transl Oncol

18. HUSSEIN S, Waley AB, Abdelgeleel HM, Saadawy SF, et al
    LC3 and beclin-1 immunohistochemical and gene expressions in bladder cancer.
    Clin Transl Oncol. 2025 Aug 5. doi: 10.1007/s12094-025-04002.
    

    >> Share

    
    

    
    Contemp Clin Trials

19. YEARY KHK, Kuliszewski MG, Yu H, Li Q, et al
    Description of a cruciferous vegetable intervention trial to test the efficacy of a maintenance component to reduce bladder cancer recurrence and progression.
    Contemp Clin Trials. 2025;156:108036.
    

    >> Share

    
    

    
    Curr Opin Urol

20. MASTROLEO F, Marvaso G, Jereczek-Fossa BA
    Artificial intelligence in muscle-invasive bladder cancer: opportunities, challenges, and clinical impact.
    Curr Opin Urol. 2025;35:543-548.
    

    >> Share

    
    

    
    Diagn Cytopathol

21. LI Y, Kanber Y, Caglar D, Kassouf W, et al
    The Spectrum of Polyoma Virus and Polyoma Virus-Like Changes in Urine Cytology: When Should an Atypical Diagnosis Be Considered.
    Diagn Cytopathol. 2025;53:447-453.
    

    >> Share

    
    

    
    Discov Oncol

22. HUANG Y, Fang S, Xie W, Zou Y, et al
    Collagen gene signature in the tumor microenvironment predicts survival and guides prognosis in bladder cancer.
    Discov Oncol. 2025;16:1479.
    

    >> Share

    
    

    
    Epigenomics

23. FANG P, Yu Y, Ma Y, Yan Y, et al
    The novel ferroptosis-inducing molecule can inhibit the progression of BC by regulating the ubiquitination of UHRF1.
    Epigenomics. 2025;17:777-791.
    

    >> Share

    
    

    
    Eur J Cancer

24. RIEGER C, Schluchtermann J, Heidenreich J, Steenbock O, et al
    Cost-effectiveness analysis of perioperative durvalumab plus platin-based chemotherapy in muscle invasive bladder cancer in Germany.
    Eur J Cancer. 2025;227:115621.
    

    >> Share

    
    

    
    Eur Urol

25. RAYCHAUDHURI R, Khaki AR, Redman MW, Baker KK, et al
    Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial.
    Eur Urol. 2025 Aug 4:S0302-2838(25)00391-4. doi: 10.1016/j.eururo.2025.
    

    >> Share

    
    

    
    Eur Urol Focus

26. LEE J, Chen F, Lopez-Beltran A, Necchi A, et al
    Urinary Tumor DNA-based Liquid Biopsy in Bladder Cancer Management: A Systematic Review.
    Eur Urol Focus. 2025 Aug 1:S2405-4569(25)00178-6. doi: 10.1016/j.euf.2025.
    

    >> Share

    
    
27. WANG H, Yang L
    Re: Mariana Silva-Ferreira, Joao A. Carvalho, Sofia Salta, et al. Diagnostic Test Accuracy of Urinary DNA Methylation-based Biomarkers for Bladder Cancer: Considerations for Further Research. Eur Urol Focus 2024;10:922-34.
    Eur Urol Focus. 2025 Aug 2:S2405-4569(25)00241-X. doi: 10.1016/j.euf.2025.
    

    >> Share

    
    
28. MAGGI M, Chierigo F, Fallara G, Jannello LMI, et al
    Shaping the Future of Personalized Therapy in Bladder Cancer Using Artificial Intelligence.
    Eur Urol Focus. 2025 Aug 1:S2405-4569(25)00216-0. doi: 10.1016/j.euf.2025.
    

    >> Share

    
    

    
    Eur Urol Oncol

29. GABRIEL PE, Roumiguie M, Marcq G, Allory Y, et al
    The Evolving Landscape of Systemic Immunotherapy for Bacillus Calmette-Guerin-naive High-risk Non-muscle-invasive Bladder Cancer: At the Edge of a Tsunami?
    Eur Urol Oncol. 2025 Aug 1:S2588-9311(25)00174-9. doi: 10.1016/j.euo.2025.
    

    >> Share

    
    

    
    Food Funct

30. ZENG Q, Cheng Y, Wang C, Chao H, et al
    Genetic influence of coffee intake on bladder cancer risk: a two-sample Mendelian randomization analysis.
    Food Funct. 2025 Aug 7. doi: 10.1039/d4fo05538.
    

    >> Share

    
    

    
    Front Immunol

31. XU Z, Yang J, Ma Y, Tao B, et al
    Exploring of bladder cancer immune-related genes and potential therapeutic targets based on transcriptomic data and Mendelian randomization analysis.
    Front Immunol. 2025;16:1607098.
    

    >> Share

    
    

    
    Front Oncol

32. GINWALA R, Bukavina L, Sindhani M, Nachman E, et al
    Bladder cancer microbiome and its association with chemoresponse.
    Front Oncol. 2025;15:1506319.
    

    >> Share

    
    

    
    Front Pharmacol

33. GUO Z, Wang W, Hu W, You W, et al
    Chemotherapeutic dihydromyricetin with remarkable anti-tumor activity and biosafety for muscle invasive bladder cancer.
    Front Pharmacol. 2025;16:1609354.
    

    >> Share

    
    

    
    Future Oncol

34. LEE T, Gianchandani A, Boorjian SA, Shore ND, et al
    Intravesical interferon-alpha2b gene therapy with nadofaragene firadenovec-vncg: a contemporary review.
    Future Oncol. 2025;21:2429-2438.
    

    >> Share

    
    

    
    Hinyokika Kiyo

35. NAKATANI M, Sasaki T, Sawai C, Inaba S, et al
    [A Case of Paraneoplastic Neurological Syndrome Caused by Bladder Cancer Manifesting as Limbic Encephalitis].
    Hinyokika Kiyo. 2025;71:239-243.
    

    >> Share

    
    

    
    Int J Biol Sci

36. NI B, Li S, Zhao L, Gao L, et al
    Novel glycoprotein SBSPON suppressed bladder cancer through the AKT signal pathway by inhibiting HSPA5 membrane translocation.
    Int J Biol Sci. 2025;21:4586-4603.
    

    >> Share

    
    

    
    Int J Surg

37. LIANG X, Liu Q, Sun X
    Comment on "Long-term impact of synchronous and metachronous bladder cancer on prognosis after radical nephroureterectomy for upper urinary tract urothelial carcinoma: results from a large population-based cohort in China.
    Int J Surg. 2025 Aug 7. doi: 10.1097/JS9.0000000000003146.
    

    >> Share

    
    

    
    Int J Urol

38. WAKAMIYA T, Yamashita S, Kohjimoto Y, Hara I, et al
    Serum Lactate Dehydrogenase Level Prior to First-Line Chemotherapy for Metastatic Urothelial Carcinoma Is a Prognostic Factor for Avelumab Maintenance Therapy: A Multicenter Retrospective Study.
    Int J Urol. 2025;32:997-1004.
    

    >> Share

    
    
39. FUKUTA K, Daizumoto K, Sasaki Y, Izumi K, et al
    Geriatric Nutritional Risk Index Predicts Postoperative Complications in Elderly Patients Undergoing Robot-Assisted Radical Cystectomy.
    Int J Urol. 2025;32:944-950.
    

    >> Share

    
    
40. WANG M, Jia B, Yang F, Han S, et al
    The Xing Technique for Intracorporeal Ileal Conduit: Outcomes From a Single Center.
    Int J Urol. 2025;32:1034-1038.
    

    >> Share

    
    

    
    J Biol Chem

41. EL-SAWY L, Rubin JR, Broses L, Patsalis C, et al
    The molecular mechanism of ambrosin induced cytotoxicity of human breast cancer and bladder cancer cells.
    J Biol Chem. 2025 Aug 1:110531. doi: 10.1016/j.jbc.2025.110531.
    

    >> Share

    
    

    
    J Clin Oncol

42. GALSKY MD, Ballas L, Kamat AM
    Muscle-Invasive Bladder Cancer: A Watershed Moment.
    J Clin Oncol. 2025 Aug 5:JCO2500718. doi: 10.1200/JCO-25-00718.
    

    >> Share

    
    

    
    J Nanobiotechnology

43. LIU Y, Xu W, Qin X, Zheng J, et al
    Intravesical delivery of mucoadhesive and tumor-selective-penetrating nanozymes for enhancing the PDT of bladder cancer.
    J Nanobiotechnology. 2025;23:554.
    

    >> Share

    
    

    
    J Nucl Med

44. HUANG W, Li L, Chao F, Yang Q, et al
    [(64)Cu]Cu-NOTA-EV-F(ab')(2) Enables Same-Day Immuno-PET Imaging of Nectin-4 in Triple-Negative Breast and Urothelial Bladder Cancers.
    J Nucl Med. 2025 Aug 7:jnumed.125.270132. doi: 10.2967/jnumed.125.270132.
    

    >> Share

    
    

    
    J Pak Med Assoc

45. ULLAH S, Gul L, Yousuf SB, Hassan B, et al
    Evaluating postoperative complications in radical cystectomy and ileal conduit for bladder cancer using the clavien-dindo grading system.
    J Pak Med Assoc. 2025;75:1053-1057.
    

    >> Share

    
    

    
    J Transl Med

46. ZHANG X, Cong Y, Zheng X, Wu G, et al
    Letter to editor: SIGMAR1 screened by a GPCR-related classifier regulates endoplasmic reticulum stress in bladder cancer.
    J Transl Med. 2025;23:874.
    

    >> Share

    
    

    
    JCO Clin Cancer Inform

47. LU K, Chao L, Wang J, Wang X, et al
    Risk Score Model of Aging-Related Genes for Bladder Cancer and Its Application in Clinical Prognosis.
    JCO Clin Cancer Inform. 2025;9:e2500019.
    

    >> Share

    
    

    
    JCO Precis Oncol

48. YUEN K, Meagher M, Mercer J, Yilma B, et al
    Comprehensive Comparison of Somatic, Germline, and Immune Cell Profiles in Upper Tract and Bladder Urothelial Carcinoma.
    JCO Precis Oncol. 2025;9:e2500289.
    

    >> Share

    
    

    
    Mod Rheumatol Case Rep

49. ANDO H, Takao K, Honda M, Kubota S, et al
    A case of irAE myositis with positive antistriational antibodies after anti-PD-L1 antibody administration: A case report.
    Mod Rheumatol Case Rep. 2025;9:rxaf025.
    

    >> Share

    
    

    
    Nat Rev Urol

50. LEE S, Sfanos K, Singla N
    The role of the urinary microbiome in genitourinary cancers.
    Nat Rev Urol. 2025;22:544-561.
    

    >> Share

    
    

    
    Neoplasia

51. ZHANG L, Jin D, Zang J, Qian L, et al
    Disitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer: a proof-of-concept study.
    Neoplasia. 2025;68:101216.
    

    >> Share

    
    

    
    Oncoimmunology

52. DE ANDREA CE, Abengozar-Muela M, Arranz JA, Climent MA, et al
    Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients.
    Oncoimmunology. 2025;14:2538687.
    

    >> Share

    
    

    
    Pan Afr Med J

53. KAYNAR K, Misir B, Ataberk HC, Mungan S, et al
    Long live the kidney despite every threats: a case report.
    Pan Afr Med J. 2025;51:35.
    

    >> Share

    
    

    
    Photodiagnosis Photodyn Ther

54. FUKUHARA H, Shigehisa R, Saito K, Hara T, et al
    Risk factors of severe prolonged hypotension induced by 5-aminolevulinic acid during photodynamic diagnosis-assisted transurethral resection of bladder tumor.
    Photodiagnosis Photodyn Ther. 2025;54:104667.
    

    >> Share

    
    
55. YAMAMOTO S, Fukuhara H, Shigehisa R, Hara T, et al
    Clinical utility of photodynamic diagnosis with 5-aminolevulinic acid hydrochloride for detecting carcinoma in situ independent of urine cytology classification.
    Photodiagnosis Photodyn Ther. 2025;54:104722.
    

    >> Share

    
    

    
    Radiography (Lond)

56. WANG Y, Sun Y, Guan L, Yang Y, et al
    Risk of secondary bladder cancer after postoperative radiotherapy for rectal cancer: A population-based cohort study.
    Radiography (Lond). 2025 Aug 4:103112. doi: 10.1016/j.radi.2025.103112.
    

    >> Share

    
    

    
    Res Vet Sci

57. AGUIRRE LS, Barbeito CG, Medina DM, Colque Caro LA, et al
    Urinary bladder lesions of bovine enzootic hematuria in Argentina.
    Res Vet Sci. 2025;193:105797.
    

    >> Share

    
    

    
    Stud Health Technol Inform

58. DAS A, Diala C, Chen G, Li Z, et al
    Efficient Training Corpus Retrieval for Large Language Model Fine Tuning: A Case Study in Cancer.
    Stud Health Technol Inform. 2025;329:1251-1255.
    

    >> Share

    
    

    
    Ther Adv Med Oncol

59. YOU C, Zhang J, Lei J, Fu W, et al
    Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States.
    Ther Adv Med Oncol. 2025;17:17588359251357519.
    

    >> Share

    
    

    
    Urol Int

60. ELLEISY M, Zettl H, Drager DL, Hakenberg OW, et al
    The Impact of Diabetes and Antidiabetics on Uro-Oncological Disease Outcomes: A Single-Center Experience.
    Urol Int. 2025;109:361-371.
    

    >> Share

    
    
61. YANG Y, Holbach S, Haas M, Engelmann SU, et al
    Does Time Matter in Early Radical Cystectomy? Comparing Outcome, Clinical, and Pathological Characteristics of Immediate versus Deferred Radical Cystectomy.
    Urol Int. 2025;109:315-322.
    

    >> Share

    
    
62. AL-NADER M, Krafft U, Darr C, Hess J, et al
    Outcomes of Surgical Therapy for Local Recurrence and Oligometastatic Urothelial Carcinoma of the Bladder: 20 Years of Experience in a Tertiary Center.
    Urol Int. 2025;109:337-345.
    

    >> Share

    
    
63. SCHNEIDEWIND L, Kiss B, Kranz J, Zengerling F, et al
    Gender-Specific Differences in Recurrence and Progression following Bacillus Calmette-Guerin Instillation for Non-Muscle-Invasive Bladder Cancer.
    Urol Int. 2025;109:412-424.
    

    >> Share

    
    

    
    Urol Oncol

64. DESANTO M, Campanelli J, Deem S
    Repeat TURBT for Ta and T1 bladder cancer: An updated review.
    Urol Oncol. 2025 Aug 2:S1078-1439(25)00257-1. doi: 10.1016/j.urolonc.2025.
    

    >> Share

    
    
65. VENKATESH A, Ishiyama Y, Rodriguez Rosales RD, Kanumuambidi JP, et al
    An RMST-based analysis of systemic therapy in muscle-invasive bladder cancer.
    Urol Oncol. 2025 Jul 31:S1078-1439(25)00252.
    

    >> Share

    
    
66. PICCOLINI A, Contieri R, Uleri A, Moretto S, et al
    Assessing oncological outcomes of bladder-sparing treatments in patients with BCG-unresponsive and BCG-exposed non-muscle-invasive bladder cancer.
    Urol Oncol. 2025 Jul 31:S1078-1439(25)00253.
    

    >> Share

    
    

    
    World J Urol

67. RODRIGUEZ PENARANDA N, Falkenbach F, Marmiroli A, Longoni M, et al
    Contemporary rates and predictors of prolonged hospital stay after radical cystectomy: a population-based analysis.
    World J Urol. 2025;43:478.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share